A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antimetabolites, Antineoplastic
  • Biomarkers, Tumor
  • Deoxycytidine
  • Equilibrative Nucleoside Transporter 1
  • Pancreatic Neoplasms

abstract

  • This study did not meet its primary endpoint and no efficacy signal was identified for CO-1.01 in treating progressive metastatic pancreas adenocarcinoma.

publication date

  • September 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4461049

Digital Object Identifier (DOI)

  • 10.1016/j.pan.2014.07.003

PubMed ID

  • 25278310

Additional Document Info

start page

  • 398

end page

  • 402

volume

  • 14

number

  • 5